Scilex Holding (SCLX) Goodwill & Intangibles (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Goodwill & Intangibles of $73.3 million for Q1 2026, down 1.31% year-over-year from $74.3 million in Q1 2025, and down 30.38% on a QoQ basis from $105.3 million in Q4 2025.
Scilex Holding (SCLX) Goodwill & Intangibles (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Goodwill & Intangibles for 6 consecutive years, with $73.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles fell 1.31% year-over-year to $73.3 million; the TTM figure through Mar 2026 stood at $73.3 million (down 1.31% YoY), while the FY2025 annual figure was $105.3 million, up 41.74% from the prior year.
- Goodwill & Intangibles came in at $73.3 million for Q1 2026 at Scilex Holding, down from $105.3 million in the prior quarter.
- The five-year high for Goodwill & Intangibles was $105.3 million in Q4 2025, with the low at $5.0 million in Q1 2022.
- Average Goodwill & Intangibles over 5 years is $53.3 million, with a median of $52.0 million recorded in 2023.
- Across the five-year window, Goodwill & Intangibles jumped 1385.62% in 2023 and plunged 39.5% in 2025, its largest moves.
- Year by year, Goodwill & Intangibles stood at $54.1 million in 2022, then surged by 37.29% to $74.3 million in 2023, then changed by 0.0% to $74.3 million in 2024, then soared by 41.74% to $105.3 million in 2025, then plunged by 30.38% to $73.3 million in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $73.3 million, $105.3 million, and $43.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.29 Mn |
| Dec 31, 2025 | 105.26 Mn |
| Sep 30, 2025 | 43.90 Mn |
| Jun 30, 2025 | 44.94 Mn |
| Mar 31, 2025 | 74.26 Mn |
| Dec 31, 2024 | 74.26 Mn |
| Sep 30, 2024 | 46.94 Mn |
| Jun 30, 2024 | 74.28 Mn |
| Mar 31, 2024 | 48.96 Mn |
| Dec 31, 2023 | 74.26 Mn |
| Sep 30, 2023 | 50.99 Mn |
| Jun 30, 2023 | 52.04 Mn |
| Mar 31, 2023 | 74.28 Mn |
| Dec 31, 2022 | 54.09 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 52.30 Mn |